Menu

Pneumatic Compression Vs Blood Flow Restriction for Muscle Recovery

Status

Enrolling

Conditions

Delayed Onset Muscle Soreness

Treatments

Device: Blood Flow Restriction
Device: Pneumatic Compression

Study type

Interventional

Funder types

Other

Identifiers

NCT06815367
HS-23-00594

Details and patient eligibility

About

Both BFR and intermittent pneumatic compression are purported to decrease symptoms associated with exercise induced muscle damage (EIMD) that cause delayed onset muscle soreness (DOMS). Blood flow restriction relies on applying pressurized cuffs to the most proximal portion of the limb. Another form of recovery often relied upon is pneumatic compression. The mechanism by which pneumatic compression works is similar to that of a massage, whereby the device progressively increases the pressure on a portion of the limb before releasing and moving further up the limb.The purpose of this study is determine whether BFR or pneumatic compression can be used to decreased DOMS which may indicate enhanced recovery.

Enrollment

33 estimated patients

Sex

All

Ages

18 to 30 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • 18-30 years of age
  • Recreationally active population
  • Women should be on a form of hormonal contraception.
  • No current musculoskeletal injuries or pathologies
  • Must answer "yes" to all PAR-Q questions.

Exclusion criteria

  • Individuals that routinely train trail running
  • Discomfort when running
  • Deep vein thrombosis
  • Blood clots
  • Cancerous lesions
  • Sensory or mental impairment
  • Unstable fractures
  • Acute pulmonary edema
  • Acute thrombophlebitis
  • Acute congestive cardiac failure
  • Acute infections
  • Episodes of pulmonary embolism
  • Wounds, lesions, infection, or tumors
  • Bone fractures or dislocations
  • Increased venous and lymphatic return
  • Answers "no" to any of the PAR-Q screening questions

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

33 participants in 3 patient groups

Control
No Intervention group
Description:
The participants will be asked to refrain from exercise 24 hours prior to and following the exercise. Participants will complete all pre-exercise tests (DOMS, CMJ, MVIC). The exercise consists of running on a treadmill situated at a -10% grade at 9 km/hr (5.59 mph) for 20 minutes. This is proceeded and followed by 5 minute warm-up/cool-down periods. Those that are allocated to the "control" group, will not receive treatment after the downhill running protocol.
Pneumatic compression
Experimental group
Description:
The participants will be asked to refrain from exercise 24 hours prior to and following the exercise. Participants will complete all pre-exercise tests (DOMS, CMJ, MVIC). The exercise consists of running on a treadmill situated at a -10% grade at 9 km/hr (5.59 mph) for 20 minutes. This is proceeded and followed by 5 minute warm-up/cool-down periods. Those allocated to the "pneumatic compression" group will receive 20 minutes of pneumatic compression at 100 mmHg.
Treatment:
Device: Pneumatic Compression
Blood flow restriction
Experimental group
Description:
The participants will be asked to refrain from exercise 24 hours prior to and following the exercise. Participants will complete all pre-exercise tests (DOMS, CMJ, MVIC). The exercise consists of running on a treadmill situated at a -10% grade at 9 km/hr (5.59 mph) for 20 minutes. This is proceeded and followed by 5 minute warm-up/cool-down periods. Those allocated to the "BFR" group will receive 4 rounds of treatment: 3 minutes will be spent at 100% of resting limb occlusion pressure, followed by 2 minutes of 0% occlusion.
Treatment:
Device: Blood Flow Restriction

Trial contacts and locations

1

There are currently no registered sites for this trial.

Central trial contact

Bailey McLagan, MS

Timeline

Last updated: Mar 25, 2025

Start date

Jan 15, 2024 • 1 year and 3 months ago

Today

Apr 27, 2025

End date

Jul 01, 2025 • in 2 months

Sponsor of this trial

Data sourced from clinicaltrials.gov